Dementia

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024

Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.

Key Points: 
  • Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
  • In September 2023, Alector completed enrollment of 381 participants in the randomized, double-blind, placebo-controlled, dose-ranging, INVOKE-2 Phase 2 clinical trial.
  • In July 2023, Alector presented an update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC).
  • Alector’s management team will host a conference call discussing Alector’s results for the fourth quarter and full year 2023 and provide a business update.

Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024

Retrieved on: 
Tuesday, February 27, 2024

MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) , taking place in Lisbon, Portugal March 5-9, 2024.

Key Points: 
  • MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) , taking place in Lisbon, Portugal March 5-9, 2024.
  • Maria Maccecchini, PhD, Founder, President, and CEO of Annovis, will join a forum discussion focused on new approaches for alpha-synuclein (αSyn), LRKK2, and GBA pathologies.
  • Aggregated αSyn is the major constituent of Lewy bodies and a pathogenic hallmark of all synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
  • It is present in a number of other neurodegenerative diseases and is responsible for axonal impairment and synaptic degeneration.

Red light therapy for neuro/cognitive benefits

Retrieved on: 
Friday, February 23, 2024

There is a simple and practical way – red light therapy to improve your brain function.

Key Points: 
  • There is a simple and practical way – red light therapy to improve your brain function.
  • Red light therapy (RLT), also known as low-level laser therapy (LLLT) or photobiomodulation (PBM), involves exposure to specific wavelengths of visible red and near-infrared light (660-850 nm) to stimulate biological processes in the body.
  • Red light therapy increases mitochondria function to promote balance between free radicals and antioxidants in the body.
  • Studies have highlighted red light therapy has a potential neuroprotective and disease-modifying role in treating Alzheimer's and Parkinson's patients.

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Retrieved on: 
Thursday, February 22, 2024

BOTHELL, Wash., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2023, and reviewed recent pipeline and business updates.

Key Points: 
  • In December 2023, the Company announced encouraging results from the exploratory Phase 2 SHAPE clinical trial to evaluate fosgonimeton in patients with Parkinson's disease dementia and dementia with Lewy bodies.
  • In May 2023, Athira selected the 40 mg dose for further development and potential regulatory approval.
  • In January 2024, Athira completed enrollment of the LIFT-AD study, randomizing approximately 315 patients in the primary analysis population.
  • In December 2023, Athira announced encouraging results from the exploratory SHAPE Phase 2 clinical trial of fosgonimeton for the potential treatment of Parkinson's disease dementia and dementia with Lewy bodies.

Firefly Neuroscience, Inc. Issues Letter to Stockholders on Proposed Merger with WaveDancer

Retrieved on: 
Thursday, February 22, 2024

FAIRFAX, Va., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) Chief Executive Officer, Jon Olsen, issues letter to stockholders ahead of Firefly’s proposed merger with WaveDancer, Inc. (“WaveDancer”) (NASDAQ: WAVD) pursuant to that definitive merger agreement, entered into on November 15, 2023, as amended on January 12, 2024 (the “Merger Agreement”).

Key Points: 
  • FAIRFAX, Va., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) Chief Executive Officer, Jon Olsen, issues letter to stockholders ahead of Firefly’s proposed merger with WaveDancer, Inc. (“WaveDancer”) (NASDAQ: WAVD) pursuant to that definitive merger agreement, entered into on November 15, 2023, as amended on January 12, 2024 (the “Merger Agreement”).
  • Stockholders are encouraged to participate in the meeting online by visiting www.virtualshareholdermeeting.com/WAVD2024SM.
  • I want to express my deepest gratitude for the ongoing support of our Firefly and WaveDancer stockholders.
  • We are on an exciting journey, and I look forward to sharing more successes with you in the future.

Sienna Senior Living Inc. Reports Strong Fourth Quarter 2023 Financial Results and Delivers 16.5% Increase in Same Property Net Operating Income

Retrieved on: 
Tuesday, February 20, 2024

Sienna's strong fourth quarter and annual results reflect the return to a stable operating environment, the Company's successful cost management strategy, and sustained reductions in temporary agency staffing costs.

Key Points: 
  • Sienna's strong fourth quarter and annual results reflect the return to a stable operating environment, the Company's successful cost management strategy, and sustained reductions in temporary agency staffing costs.
  • Q4 2023 marks the fourth consecutive quarter of significant year over year same property net operating income (“NOI”) growth in the Company’s long-term care and retirement segments.
  • “Sienna’s consistently strong financial performance in 2023 indicates that we are on the right track.”
    Same-property NOI increased by 16.5% to $37.7 million in Q4 2023, compared to Q4 2022, including
    a 11.8% increase in the retirement segment.
  • The increase was primarily related to the increase in OFFO, offset by higher maintenance capital expenditures, and a decrease in construction funding income.

California Launches New Campaign to Take on Alzheimer’s

Retrieved on: 
Thursday, March 7, 2024

Take On Alzheimer’s will counter hesitation and delays by increasing education and encouraging conversations across all communities.

Key Points: 
  • Take On Alzheimer’s will counter hesitation and delays by increasing education and encouraging conversations across all communities.
  • It educates diverse communities about signs, risk factors, and ways to promote brain health.
  • WHY CALIFORNIANS SHOULD CARE: The primary risk factor for Alzheimer’s is age, and California is home to more adults aged 65 and older than any other state.
  • Since that time, the Governor and state legislature have made funding available for CDPH and the Alzheimer’s Disease Program, in turn supporting things like the California Healthy Brain Initiative , California Alzheimer’s Disease Centers , and various program research grants .

CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference

Retrieved on: 
Thursday, March 7, 2024

The oral presentation will take place at AD/PD™ 2024: The International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, being held March 5-9, 2024, in Lisbon, Portugal.

Key Points: 
  • The oral presentation will take place at AD/PD™ 2024: The International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, being held March 5-9, 2024, in Lisbon, Portugal.
  • CST-2032 is one of CuraSen’s two lead product candidates being tested in patients with Alzheimer’s and Parkinson’s disease.
  • Both CST-2032 and CST-103 work by enabling reactivation of brain adrenergic function lost early in the neurodegenerative disease process.
  • Target effect sizes of 0.2-0.3 or higher, as seen in this study, predict success in larger, longer studies.

Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial

Retrieved on: 
Thursday, March 7, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240307066794/en/
    New 24-month data show sustained benefits across the disease spectrum from early to moderate dementia.
  • Analyses comparing the study participants to closely matched real world data and meta-analytical controls, showed significantly reduced disease progression in participants in the LUCIDITY trial.
  • In the early disease subgroup there was a significant reduction in transition to the dementia stage of AD.
  • Its secondary pharmacological action is symptomatic through increasing acetylcholine levels in parts of the brain essential for memory functions.

C₂N Diagnostics, LLC Announces Investment From Eisai Inc.

Retrieved on: 
Wednesday, March 6, 2024

C₂N Diagnostics, LLC , a leader in advanced brain health diagnostics, and Eisai Inc. , a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.

Key Points: 
  • C₂N Diagnostics, LLC , a leader in advanced brain health diagnostics, and Eisai Inc. , a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.
  • C₂N executives say the investment reflects the two companies’ shared desire to scale up and provide broad access to its Precivity™ tests , which are innovative blood tests intended for use in patients with cognitive impairment.
  • These tests aim to help healthcare providers determine Alzheimer’s disease pathology, and aid in medical management and treatment decisions.
  • “Given the expense and capacity limitations of PET and CSF tests, Eisai is working to support the dementia ecosystem’s growth.